Quidel Corp
XBER:QL1

Watchlist Manager
Quidel Corp Logo
Quidel Corp
XBER:QL1
Watchlist
Price: 98.5 EUR -1.01% Market Closed
Market Cap: €4.1B

Net Margin

-43.4%
Current
Declining
by 16.9%
vs 3-y average of -26.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-43.4%
=
Net Income
$-1.2B
/
Revenue
$2.7B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-43.4%
=
Net Income
€-1.2B
/
Revenue
$2.7B

Peer Comparison

Country Company Market Cap Net
Margin
US
Quidel Corp
NASDAQ:QDEL
1.8B USD
Loading...
US
Medline Inc
NASDAQ:MDLN
58.4B USD
Loading...
JP
Hoya Corp
TSE:7741
8.8T JPY
Loading...
CH
Alcon AG
SIX:ALC
30.8B CHF
Loading...
DK
Coloplast A/S
CSE:COLO B
120.8B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
11.7B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.7B GBP
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
42.2B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
5.9B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.2B CHF
Loading...
KR
HLB Inc
KOSDAQ:028300
7.3T KRW
Loading...

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 15 072 companies
20th percentile
-43.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Quidel Corp
Glance View

Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.

QL1 Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-43.4%
=
Net Income
$-1.2B
/
Revenue
$2.7B
What is Quidel Corp's current Net Margin?

The current Net Margin for Quidel Corp is -43.4%, which is below its 3-year median of -26.5%.

How has Net Margin changed over time?

Over the last 3 years, Quidel Corp’s Net Margin has decreased from 26.7% to -43.4%. During this period, it reached a low of -73.7% on Dec 29, 2024 and a high of 26.7% on Oct 2, 2022.

Back to Top